Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Effect of Furlow Palatoplasty With Buccal Myomucosal Flap on the Speech Development

NCT06856330 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-03-25
Last updated
2025-07-28

Condition(s) studied

Cleft Palate

Investigational drug(s) / intervention(s)

furlow with buccal myomucosal flaptwo flap palatoplasty

furlow with buccal myomucosal flap: patients were treated with furlow with buccal myomucosal flap

two flap palatoplasty: patients were treated with two flap palatoplasty

Study summary

About 20 patient will be collected according to the eligibility criteria and grouped into Group I : 10 patients were treated with furlow with buccinators flap Group II : 10 patients were treated with 2 flap palatoplasty All patients will be examined by an expert Phoniatrician by Recording of speech samples in Arabic language for the children in a soundproof room including repeated syllables, sentences with high-pressure sounds and counting from 1 to 10. The records will be analyzed to assess the degree of hypernasality, speech intelligibility and compensatory speech errors

Eligibility

Sex
ALL
Min age
3 Years
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: * 3-5 years old childreen with previous treated complete cleft lip and palate, nonsyndromic. * lip and palate repair performed by one craniofacial surgeon Exclusion Criteria: * Patients with syndromic cleft lip. * Redu cases * Bilateral cleft lip * Patient older 5years or younger 3 years. * Associated Cardiac anomalies. * Any systemic condition

Primary outcome measure(s)

  • nasopharyngoscopic examination — through study completion, an average one week
    this will be done through the nasopharyngoscopic examination of the cleft patients after repair with Furlow with buccinator flap versus two flap palatoplasty. it will assess the grade of velopharyngeal closure during speech

Trial sites (1)

FacilityCityRegionStatus
Fayoum University Al Fayyum Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06856330 on ClinicalTrials.gov ↗ ← All trials in Egypt